These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
433 related articles for article (PubMed ID: 15472782)
1. [Atomoxetine for the treatment of attention-deficit/hyperactivity disorder]. Davids E; Gastpar M Fortschr Neurol Psychiatr; 2004 Oct; 72(10):586-91. PubMed ID: 15472782 [TBL] [Abstract][Full Text] [Related]
2. Quality of life assessment in adult patients with attention-deficit/hyperactivity disorder treated with atomoxetine. Adler LA; Sutton VK; Moore RJ; Dietrich AP; Reimherr FW; Sangal RB; Saylor KE; Secnik K; Kelsey DK; Allen AJ J Clin Psychopharmacol; 2006 Dec; 26(6):648-52. PubMed ID: 17110824 [TBL] [Abstract][Full Text] [Related]
3. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study. Dell'Agnello G; Maschietto D; Bravaccio C; Calamoneri F; Masi G; Curatolo P; Besana D; Mancini F; Rossi A; Poole L; Escobar R; Zuddas A; Eur Neuropsychopharmacol; 2009 Nov; 19(11):822-34. PubMed ID: 19716683 [TBL] [Abstract][Full Text] [Related]
4. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study. Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731 [TBL] [Abstract][Full Text] [Related]
5. Atomoxetine treatment outcomes in adolescents and young adults with attention-deficit/hyperactivity disorder: results from a post hoc, pooled analysis. Adler LA; Wilens T; Zhang S; Dittmann RW; D'Souza DN; Schuh L; Durell TM Clin Ther; 2012 Feb; 34(2):363-73. PubMed ID: 22285724 [TBL] [Abstract][Full Text] [Related]
6. Atomoxetine for attention deficit/hyperactivity disorder. Garces K Issues Emerg Health Technol; 2003 May; (46):1-4. PubMed ID: 12751480 [TBL] [Abstract][Full Text] [Related]
7. Atomoxetine. Attention-deficit/hyperactivity disorder: no better than methylphenidate. Prescrire Int; 2010 Feb; 19(105):5-8. PubMed ID: 20455329 [TBL] [Abstract][Full Text] [Related]
8. Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: a randomized, double-blind, placebo-controlled clinical trial. Durell TM; Adler LA; Williams DW; Deldar A; McGough JJ; Glaser PE; Rubin RL; Pigott TA; Sarkis EH; Fox BK J Clin Psychopharmacol; 2013 Feb; 33(1):45-54. PubMed ID: 23277268 [TBL] [Abstract][Full Text] [Related]
9. A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder. Harfterkamp M; van de Loo-Neus G; Minderaa RB; van der Gaag RJ; Escobar R; Schacht A; Pamulapati S; Buitelaar JK; Hoekstra PJ J Am Acad Child Adolesc Psychiatry; 2012 Jul; 51(7):733-41. PubMed ID: 22721596 [TBL] [Abstract][Full Text] [Related]
10. Comparison of parent and teacher reports of attention-deficit/hyperactivity disorder symptoms from two placebo-controlled studies of atomoxetine in children. Biederman J; Gao H; Rogers AK; Spencer TJ Biol Psychiatry; 2006 Nov; 60(10):1106-10. PubMed ID: 16806096 [TBL] [Abstract][Full Text] [Related]
12. A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder. Biederman J; Wigal SB; Spencer TJ; McGough JJ; Mays DA Clin Ther; 2006 Feb; 28(2):280-93. PubMed ID: 16678649 [TBL] [Abstract][Full Text] [Related]
13. Atomoxetine: a new pharmacotherapeutic approach in the management of attention deficit/hyperactivity disorder. Barton J Arch Dis Child; 2005 Feb; 90 Suppl 1(Suppl 1):i26-9. PubMed ID: 15665154 [TBL] [Abstract][Full Text] [Related]
14. Atomoxetine treatment of attention-deficit/hyperactivity disorder. Eiland LS; Guest AL Ann Pharmacother; 2004 Jan; 38(1):86-90. PubMed ID: 14742801 [TBL] [Abstract][Full Text] [Related]
15. Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. Wernicke JF; Kratochvil CJ J Clin Psychiatry; 2002; 63 Suppl 12():50-5. PubMed ID: 12562062 [TBL] [Abstract][Full Text] [Related]
16. Atomoxetine: a selective noradrenaline reuptake inhibitor for the treatment of attention-deficit/hyperactivity disorder. Kratochvil CJ; Vaughan BS; Harrington MJ; Burke WJ Expert Opin Pharmacother; 2003 Jul; 4(7):1165-74. PubMed ID: 12831341 [TBL] [Abstract][Full Text] [Related]
18. Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders. Wilens TE; Adler LA; Weiss MD; Michelson D; Ramsey JL; Moore RJ; Renard D; Brady KT; Trzepacz PT; Schuh LM; Ahrbecker LM; Levine LR; Drug Alcohol Depend; 2008 Jul; 96(1-2):145-54. PubMed ID: 18403134 [TBL] [Abstract][Full Text] [Related]
19. Safety and tolerability of once versus twice daily atomoxetine in adults with ADHD. Adler L; Dietrich A; Reimherr FW; Taylor LV; Sutton VK; Bakken R; Allen AJ; Kelsey D Ann Clin Psychiatry; 2006; 18(2):107-13. PubMed ID: 16754416 [TBL] [Abstract][Full Text] [Related]
20. Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study. Adler LA; Spencer TJ; Williams DW; Moore RJ; Michelson D J Atten Disord; 2008 Nov; 12(3):248-53. PubMed ID: 18448861 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]